Assessing FLAURA2's Influence: How Has It Shaped Your First-Line Treatment Strategy?

August 23, 2024

By Martin Dietrich, MD, PhD
Wade Iams, MD

Opinion

Video

Following the 2024 ASCO Annual Meeting, medical oncologists share insights on how the availability of the FLAURA2 treatment regimen has impacted the treatment of patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC).

Now Viewing

EP: 1.Assessing FLAURA2's Influence: How Has It Shaped Your First-Line Treatment Strategy?

EP: 2.Evaluating MARIPOSA’s Secondary Analysis in High-Risk Advanced EGFR-Mutant NSCLC: Practical Implications

EP: 3.Expert Insights from PALOMA-3: Highlights from ASCO 2024

EP: 4.Subcutaneous Amivantimab: Overcoming Treatment Barriers and Shaping Advanced NSCLC Strategies

EP: 5.Implementing Proactive Management Strategies with Amivantamab in Clinical Practice: Expert Insights

EP: 6.Insights from TROPION-Lung05 and HERTHENA-Lung01: Perspectives on the Future Role of ADCs in Advanced EGFR-Mutant NSCLC

EP: 7.Other Trials and Emerging Data in EGFR-Mutant NSCLC Treatment: Anticipating the Future Treatment Landscape

Video content above is prompted by the following:

What impact has the availability of FLAURA2 had on your 1L treatment approach? How are you using FLAURA2 in your practice?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!